Gossamer Bio appoints Gregory Ciongoli to board, adds him to Audit Committee
Gossamer Bio appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with a term expiring at the 2027 annual meeting, and also named him to the Audit Committee. The Board determined he is independent under Nasdaq listing rules, and he is a purchaser in the 2026 private placement, so his board seat ties him to securities he has agreed to buy in the company.
Key points
- Appointed Class III director effective September 16, 2026; initial term expires at the 2027 annual meeting of stockholders
- Receives a $40,000 annual cash retainer for Board service and a $7,500 annual cash retainer for Audit Committee service
- Purchased initial closing pre-funded warrants in the 2026 PIPE (initial closing August 24, 2026) and agreed to buy second closing and FDA approval warrants
- Board determined he is independent under Nasdaq Global Select Market listing requirements
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.